C
Cyclerion Therapeutics, Inc. (CYCN)
NCM – Real Time Price. Currency in USD
3.38
+0.21 (6.62%)
At close: Jun 26, 2026, 4:00 PM EDT
3.31
-0.07 (-2.07%)
After-hours: Jun 26, 2026, 7:32 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
3.38
+0.21 (6.62%)
At close: Jun 26, 2026, 4:00 PM EDT
3.31
-0.07 (-2.07%)
After-hours: Jun 26, 2026, 7:32 PM EDT
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Regina M. Graul Ph.D. | CEO, President & Director |
| Ms. Rhonda M. Chicko CPA | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-09 | S-4/A | d111069ds4a.htm |
| 2026-05-12 | 10-Q | cycn-20260331.htm |
| 2026-04-30 | 10-K/A | cycn-20251231.htm |
| 2026-04-20 | S-4 | d111069ds4.htm |
| 2026-04-01 | 8-K | d128275d8k.htm |
| 2026-04-01 | 425 | d128275d425.htm |
| 2026-03-31 | 10-K | cycn-20251231.htm |
| 2026-02-17 | 8-K | d104475d8k.htm |
| 2026-01-06 | 8-K | d23253d8k.htm |
| 2025-12-01 | 8-K | d48096d8k.htm |